A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1

Active:	No
Cancer Type:	Brain & Spinal Cord Tumor Brain Tumor Unknown Primary	NCT ID:	NCT03776071
Trial Phases:	Phase III	Protocol IDs:	DB102-01 (primary) NCI-2020-13730
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Denovo Biopharma LLC
NCI Full Details:	http://clinicaltrials.gov/show/NCT03776071

Summary

This study will be conducted as a randomized, double-blind, placebo-controlled,
multi-center Phase 3 study. Approximately 300 subjects with newly diagnosed glioblastoma
who meet all eligibility criteria will be enrolled.

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.